The Emodin exerts its anti-cancer activities in pancreatic cancer cells through declining the mitochondrial membrane potential.43 The Emodin Azide Methyl Anthraquinone Derivative (AMAD) was found to effectively block phosphorylation of Her2/neu, suppress growth, transformation and metastasis as a tyrosine kinase inhibitor, and increase the susceptibility of Her2/neu-over expressing cancer cells to standard cytotoxic therapeutic agents. Here, ERBB2 is linked to pancreatic neoplasm.